Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-17 (Cancelled)

18. (Currently Amended) A compound represented by the following structural formula:



or physiologically acceptable salts thereof, wherein:

R is selected from the group consisting of substituted or unsubstituted~~: indolyl, imidazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, benzimidazolyl, 4,5,6,7-tetrahydroindolyl, benzoindolyl, azaindolyl, indazolyl, pyridinyl, quinolinyl, pyrimidinyl, phenyl, pyrazinyl,~~ pyrrolyl~~, pyrazolyl, oxazolyl and thiazolyl~~;

wherein R can be substituted by one or more halogen, lower alkyl group, R^3O-, hydroxyl, HOC(O), $R^3OC(O)$-, $R^3OC(O)R^6$-, R^3OR^6-, trihalomethyl, trihalomethylcarbonyl, nitro, -$C(O)NR^4R^5$, -NR^4R^5, R^3CO-, -$(CH_2)_nR^7$, -$C(O)(CH_2)_n$-R^7, -$C(O)(CH_2)_n$-C(O)-R^7, -$O(CH_2)_nR^7$, -$C(O)NR^4(CH_2)_nR^7$, -$C(O)O(CH_2)_nR^7$, -$OC(O)(CH_2)_nR^7$, -$NR^4C(O)(CH_2)_nR^7$, -$R^6NR^4R^5$, -$R^6N(R^4)$-R^6-R^7, -$R^6N(R^6$-$R^7)_2$, -$R^6C(O)NR^4(CH_2)_nR^7$, -$R^6C(O)O(CH_2)_nR^7$, -$R^6OC(O)(CH_2)_nR^7$, -$R^6NR^4C(O)(CH_2)_nR^7$, -$R^6CH(C(O)OR^4(NR^5C(O)R^4)$ or a substituted aryl or aralkyl group, wherein the substituent is selected from the group consisting of halogen, trihalomethyl, hydroxy, -NR^4R^5, nitro, -$CONR^4R^5$, lower alkyl group, R^3O-, -$C(O)OR^4$ or –$OC(O)R^3$;

wherein R^6 is a lower alkyl group or an aryl group;

wherein R^7 is alkoxy, haloalkyl, lower alkyl piperazine, hydroxyl, R^3O-, $R^3C(O)$- or –NR^4R^5;

wherein suitable substituents for R^3, R^4 and R^5 can be one or more moieties selected from the group consisting of halogens, lower alkyl, hydroxy, lower alkoxy, carboxy, lower alkyl ester,

trihalomethyl, nitro, phenyl, phenyl-lower alkyl, (C_3-C_6)cycloalkyl, (C_3-C_6)cycloalkyl-alkyl, CN, amino, alkylamino, dialkylamino, -C(O)NH_2, -C(O)NH(alkyl) and –C(O)N(alkyl)$_2$;

R^1 is hydrogen or -A-Z;

A is ~~–$(CH_2)_n$-, $(CH_2)_nNH$-, $(CH_2)_nO$-, $(CH_2)_nS$-, $(CH_2)_nS(O)$- or $(CH_2)_nS(O)_2$-~~;

Z is ~~-H, a lower alkyl, aralkyl, trihalomethyl, trihalomethylcarbonyl, $R^3OC(O)$-, NR^4R^5-, C(O)NR^4R^5-, R^3CO-, R^3O-, or-~~ a ring system selected from the group consisting of ~~a C_3-C_6-cycloalkyl, isoxazolyl, isothiazolyl, imidazolyl,~~ phenyl~~, pyrrolyl, indolyl, pyridinyl,~~ pyrazinyl, ~~pyrimidinyl, benzothiazolyl, tetrahydrofuranyl, thiophenyl, imidazolyl, furanyl, triazinyl, benzimidazolyl, pyridazinyl, quinoxalinyl, pyrazolyl, oxazolyl, thiazolyl and the N-oxides thereof~~ wherein said ring system can be optionally substituted with one or more moieties selected from the group consisting of halogens, lower alkyl, R^3O-, HO-, HOC(O)-, $R^3OC(O)$-, trihalomethyl, nitro, an aromatic group, a (C_3-C_6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C_3-C_6)cycloalkyl-alkyl group, a heterocyclyl-alkyl group, -CN, -C(O)NR^4R^5 or -NR^4R^5;

R^3 for each occurrence is, independently selected from the group consisting of substituted or unsubstituted: lower alkyl group, lower alkoxy lower alkyl group, aromatic group, (C_3-C_6)cycloalkyl group, heterocyclic group, aralkyl group, a (C_3-C_6)cycloalkyl-alkyl group, and heterocyclyl-alkyl group;

R^4 and R^5 for each occurrence are each, independently, hydrogen, or are selected from the group consisting of substituted or unsubstituted: lower alkyl group, aromatic group, (C_3-C_6)cycloalkyl group, heterocyclic group, aralkyl group, a (C_3-C_6)cycloalkyl-alkyl group, and heterocyclyl-alkyl group;

optionally, R^4 and R^5 together with the nitrogen to which they are attached represent morpholino, pyrrolidino, piperidino, imidazol-1-yl, piperazino, thiamorpholino, azepino or perhydro-1,4-diazepin-1-yl groups each optionally substituted by one or more moieties selected from the group consisting of lower alkyl, hydroxy, lower alkoxy lower alkyl, an aromatic group, a (C_3-C_6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C_3-C_6)cycloalkyl-alkyl group, and a heterocyclyl-alkyl group; and

n is ~~an integer from~~ 0 ~~to 3;~~ .

~~provided that when R is an unsubstituted indol-3-yl then R^1 is not NH_2;~~

~~and~~

~~provided that the compound is not~~



~~and~~

~~provided that when R^1 is methyl, R is not hydroxyphenyl, nitrophenyl, m-$OCH_3C_6H_4$, 4-hydroxy-3-methoxyphenyl or 2-hydroxy-3-bromophenyl.~~

19. (Cancelled) The compound of Claim 18 wherein:

A is –NH-, -O-, -S-, -S(O)- or –S(O)2-; and

Z is cyclopropyl, 3-pyridyl or pyrazinyl.

20. (Cancelled) The compound of Claim 18 wherein:

A is –O-; and

Z is ethyl, n-propyl or isopropyl.

21. (Cancelled) The compound of Claim 18 wherein:

A is –CH_2-; and

Z is phenyl, wherein said phenyl is optionally substituted with one or more moieties selected from the group consisting of halogens, trihalomethyl, hydroxyl, $-NR^4R^5$, nitro $-CONR^4R^5$, lower alkyl group, R^3O-, $-C(O)OR^4$ and $-OC(O)R^4$.

22. (Cancelled)

23. (Original) The compound of Claim 18 wherein the compound is a mixture of stereoisomers.

24. (Original) The compound of Claim 23 wherein the stereoisomers are enantiomers.

25. (Original) The compound of Claim 24 wherein the stereoisomers are E and Z isomers.

26. (Original) The compound of claim 18 wherein the compound is a mixture of structural isomers.

27. (Original) The compound of claim 26 wherein the structural isomers are tautomers.

28. (Currently Amended) A method of inhibiting one or more protein kinase activities selected from the group of protein kinases consisting of KDR/VEGFR-2, Flt-1/VEGFR-1, FGFR, PDGFR, IGF-1R, c-Met, Lck, Src, fyn, yes, PKC, MAP kinases, erk, CDKs, Plk-1 and Raf-1comprising the administration to an individual in need thereof of a compound represented by the following structural formula:



or physiologically acceptable salts thereof, wherein:

R is selected from the group consisting of substituted or unsubstituted: indolyl, imidazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, benzimidazolyl, 4,5,6,7-tetrahydroindolyl, benzoindolyl, azaindolyl, indazolyl, pyridinyl, quinolinyl, pyrimidinyl, phenyl, pyrazinyl, pyrrolyl, pyrazolyl, oxazolyl and thiazolyl;

R^1 is hydrogen or -A-Z;

A is $-(CH_2)_n-$, $-(CH_2)_nNH-$, $-(CH_2)_nO-$, $-(CH_2)_nS-$, $-(CH_2)_nS(O)-$ or $-(CH_2)_nS(O)_2-$;

Z is -H, a lower alkyl, aralkyl, trihalomethyl, trihalomethylcarbonyl, $R^3OC(O)$-, $-NR^4R^5$, $-C(O)NR^4R^5$, R^3CO-, R^3O-, or a ring system selected from the group consisting of a C_3-C_6 cycloalkyl, isoxazolyl, isothiazolyl, imidazolyl, phenyl, pyrrolyl, indolyl, pyridinyl, pyrazinyl, pyrimidinyl, benzothiazolyl, tetrahydrofuranyl, thiophenyl, imidazolyl, furanyl, triazinyl, benzimidazolyl, pyridazinyl, quinoxalinyl, pyrazolyl, oxazolyl, thiazolyl and the N-oxides thereof wherein said ring system can be optionally substituted with one or more moieties selected from the group consisting of halogens, lower alkyl, R^3O-, HO-, HOC(O)-, $R^3OC(O)$-, trihalomethyl, nitro, an aromatic group, a (C_3-C_6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C_3-C_6)cycloalkyl-alkyl group, a heterocyclyl-alkyl group, -CN, $-C(O)NR^4R^5$ or $-NR^4R^5$;

R^3 for each occurrence is, independently selected from the group consisting of substituted or unsubstituted: lower alkyl group, lower alkoxy lower alkyl group, aromatic group, (C_3-C_6)cycloalkyl group, heterocyclic group, aralkyl group, a (C_3-C_6)cycloalkyl-alkyl group, and heterocyclyl-alkyl group;

R^4 and R^5 for each occurrence are each, independently, hydrogen, or are selected from the group consisting of substituted or unsubstituted: lower alkyl group, aromatic group, (C_3-C_6)cycloalkyl group, heterocyclic group, aralkyl group, a (C_3-C_6)cycloalkyl-alkyl group, and heterocyclyl-alkyl group;

optionally, R^4 and R^5 together with the nitrogen to which they are attached represent morpholino, pyrrolidino, piperidino, imidazol-1-yl, piperazino, thiamorpholino, azepino or perhydro-1,4-diazepin-1-yl groups each optionally substituted by one or more moieties selected from the group consisting of lower alkyl, hydroxy, lower alkoxy lower alkyl, an aromatic group, a (C_3-C_6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C_3-C_6)cycloalkyl-alkyl group, and a heterocyclyl-alkyl group; and

n is an integer from 0 to 3;

provided that when R is an unsubstituted indol-3-yl then R^1 is not $-NH_2$;.

29. (Cancelled)

30. (Currently Amended) The method of Claim ~~29~~ 28 wherein the compound is a mixture of stereosiomers.

31. (Original) The method of Claim 30 wherein the stereoisomers are enantiomers.

32. (Original) The method of Claim 30 wherein the stereoisomers are E and Z isomers.

33. (Original) The method of Claim 29 wherein the compound is a mixture of structural isomers.

34. (Original) The method of Claim 29 wherein the structural isomers are tautomers.

35. (Original) The method of claim 29 wherein said protein kinase is a tyrosine kinase.

36. (Original) The method according to Claim 35 wherein said tyrosine kinase is selected from the group consisting of KDR, Flt-1, TIE-2, Lck, Src, fyn, Lyn, Blk, and yes.

37. (Previously Presented) A method of affecting macular degeneration, solid tumors, malignant ascites, hematopoietic cancers, thyroid hyperplasia, Grave's disease, cysts, and polycystic ovarian syndrome in a recipient comprising the administration of a compound represented by the following structural formula:



or physiologically acceptable salts thereof, wherein:

R is selected from the group consisting of substituted or unsubstituted: indolyl, imidazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, benzimidazolyl, 4,5,6,7-tetrahydroindolyl, benzoindolyl, azaindolyl, indazolyl, pyridinyl, quinolinyl, pyrimidinyl, phenyl, pyrazinyl, pyrrolyl, pyrazolyl, oxazolyl and thiazolyl;

wherein R can be substituted by halogens, lower alkyl groups, R^3O-, hydroxyl, HOC(O), $R^3OC(O)$-, $R^3OC(O)R^6$-, R^3OR^6-, trihalomethyl, trihalomethylcarbonyl, nitro, $-C(O)NR^4R^5$, $-NR^4R^5$, R^3CO-, $-(CH_2)_nR^7$, $-C(O)(CH_2)_n-R^7$, $-C(O)(CH_2)_n-C(O)-R^7$, $-O(CH_2)_nR^7$, $-C(O)NR^4(CH_2)_nR^7$-, $-C(O)O(CH_2)_nR^7$, $-OC(O)(CH_2)_nR^7$, $-NR^4C(O)(CH_2)_nR^7$, $-R^6NR^4R^5$, $-R^6N(R^4)-R^6-R^7$, $-R^6N[R^6-R^7]_2$, $-R^6C(O)NR^4(CH_2)_nR^7$, $-R^6C(O)O(CH_2)_nR^7$, $-R^6OC(O)(CH_2)_nR^7$, $-R^6NR^4C(O)(CH_2)_nR^7$, $-R^6CH[C(O)OR^4][NR^5C(O)R^4]$ or a substituted aryl or aralkyl group,

wherein the substituent is selected from the group consisting of halogen, trihalomethyl, hydroxy, -NR^4R^5, nitro, -$CONR^4R^5$, lower alkyl group, R^3O-, -$C(O)OR^4$ or –$OC(O)R^3$;

wherein R^6 is a lower alkyl group or an aryl group;

wherein R^7 is alkoxy, haloalkyl, lower alkyl piperazine, hydroxyl, R^3O-, $R^3C(O)$- or –NR^4R^5;

wherein suitable substituents for R^3, R^4 and R^5 can be one or more moieties selected from the group consisting of halogens, lower alkyl, hydroxy, lower alkoxy, carboxy, lower alkyl ester, trihalomethyl, nitro, phenyl, phenyl-lower alkyl, (C_3-C_6)cycloalkyl, (C_3-C_6)cycloalkyl-alkyl, CN, amino, alkylamino, dialkylamino, -$C(O)NH_2$, -C(O)NH(alkyl) and –$C(O)N(alkyl)_2$;

R^1 is hydrogen or -A-Z;

A is –$(CH_2)_n$-, -$(CH_2)_nNH$-, -$(CH_2)_nO$-, -$(CH_2)_nS$-, -$(CH_2)_nS(O)$- or -$(CH_2)_nS(O)_2$-;

Z is -H, a lower alkyl, aralkyl, trihalomethyl, trihalomethylcarbonyl, $R^3OC(O)$-, -NR^4R^5, -$C(O)NR^4R^5$, R^3CO-, R^3O-, or a ring system selected from the group consisting of a C_3-C_6 cycloalkyl, isoxazolyl, isothiazolyl, imidazolyl, phenyl, pyrrolyl, indolyl, pyridinyl, pyrazinyl, pyrimidinyl, benzothiazolyl, tetrahydrofuranyl, thiophenyl, imidazolyl, furanyl, triazinyl, benzimidazolyl, pyridazinyl, quinoxalinyl, pyrazolyl, oxazolyl, thiazolyl and the N-oxides thereof wherein said ring system can be optionally substituted with one or more moieties selected from the group consisting of halogens, lower alkyl, R^3O-, HO-, HOC(O)-, $R^3OC(O)$-, trihalomethyl, nitro, an aromatic group, a (C_3-C_6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C_3-C_6)cycloalkyl-alkyl group, a heterocyclyl-alkyl group, -CN, -$C(O)NR^4R^5$ or -NR^4R^5;

R^3 for each occurrence is, independently selected from the group consisting of substituted or unsubstituted: lower alkyl group, lower alkoxy lower alkyl group, aromatic group, (C_3-C_6)cycloalkyl group, heterocyclic group, aralkyl group, a (C_3-C_6)cycloalkyl-alkyl group, and heterocyclyl-alkyl group;

R^4 and R^5 for each occurrence are each, independently, hydrogen, or are selected from the group consisting of substituted or unsubstituted: lower alkyl group, aromatic group, (C_3-C_6)cycloalkyl group, heterocyclic group, aralkyl group, a (C_3-C_6)cycloalkyl-alkyl group, and heterocyclyl-alkyl group;

optionally, R^4 and R^5 together with the nitrogen to which they are attached represent morpholino, pyrrolidino, piperidino, imidazol-1-yl, piperazino, thiamorpholino, azepino or perhydro-1,4-diazepin-1-yl groups each optionally substituted by one or more moieties selected from the group consisting of lower alkyl, hydroxy, lower alkoxy lower alkyl, an aromatic group, a

(C_3-C_6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C_3-C_6)cycloalkyl-alkyl group, and a heterocyclyl-alkyl group; and

n is an integer from 0 to 3;

provided that when R is an unsubstituted indol-3-yl then R^1 is not $-NH_2$;

to said recipient.

38. (Previously Presented) A method of affecting arthritis, atherosclerosis, psoriasis, hemangiomas, myocardial angiogenesis, coronary and cerebral collaterals, ischemic limb angiogenesis, wound healing, peptic ulcer Helicobacter related diseases, virally-induced angiogenic disorders, fractures, Crow-Fukase syndrome (POEMS), preeclampsia, menometrorrhagia, cat scratch fever, rubeosis, neovascular glaucoma, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, solid tumors, malignant ascites, hemopoietic cancers, Herpes simplex, Herpes Zoster, AIDS, parapoxvirus, psoriasis, Kaposi's sarcoma, protozoan infections and toxoplasmosis, endometriosis, ovarian hyperstimulation syndrome, preeclampsia, systemic lupus, sarcoidosis, synovitis, inflammatory bowel disease, Crohn's disease, sickle cell anaemia, Lyme's disease, pemphigoid, Paget's disease, hyperviscosity syndrome, Osler-Weber-Rendu disease, chronic inflammation, chronic occlusive pulmonary disease, asthma, rheumatoid arthritis and osteosarthritis in a recipient comprising the administration of a compound represented by the following structural formula:



or physiologically acceptable salts thereof, wherein:

R is selected from the group consisting of substituted or unsubstituted: indolyl, imidazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, benzimidazolyl, 4,5,6,7-tetrahydroindolyl, benzoindolyl, azaindolyl, indazolyl, pyridinyl, quinolinyl, pyrimidinyl, phenyl, pyrazinyl, pyrrolyl, pyrazolyl, oxazolyl and thiazolyl;

R^1 is hydrogen or -A-Z;

A is $-(CH_2)_n-$, $-(CH_2)_nNH-$, $-(CH_2)_nO-$, $-(CH_2)_nS-$, $-(CH_2)_nS(O)-$ or $-(CH_2)_nS(O)_2-$;

Z is -H, a lower alkyl, aralkyl, trihalomethyl, trihalomethylcarbonyl, $R^3OC(O)-$,

$-NR^4R^5$, $-C(O)NR^4R^5$, R^3CO-, R^3O-, or a ring system selected from the group consisting of a C_3-C_6 cycloalkyl, isoxazolyl, isothiazolyl, imidazolyl, phenyl, pyrrolyl, indolyl, pyridinyl, pyrazinyl, pyrimidinyl, benzothiazolyl, tetrahydrofuranyl, thiophenyl, imidazolyl, furanyl, triazinyl, benzimidazolyl, pyridazinyl, quinoxalinyl, pyrazolyl, oxazolyl, thiazolyl and the N-oxides thereof wherein said ring system can be optionally substituted with one or more moieties selected from the group consisting of halogens, lower alkyl, R^3O-, HO-, HOC(O)-, $R^3OC(O)-$, trihalomethyl, nitro, an aromatic group, a (C_3-C_6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C_3-C_6)cycloalkyl-alkyl group, a heterocyclyl-alkyl group, -CN, $-C(O)NR^4R^5$ or $-NR^4R^5$;

R^3 for each occurrence is, independently selected from the group consisting of substituted or unsubstituted: lower alkyl group, lower alkoxy lower alkyl group, aromatic group, (C_3-C_6)cycloalkyl group, heterocyclic group, aralkyl group, a (C_3-C_6)cycloalkyl-alkyl group, and heterocyclyl-alkyl group;

R^4 and R^5 for each occurrence are each, independently, hydrogen, or are selected from the group consisting of substituted or unsubstituted: lower alkyl group, aromatic group, (C_3-C_6)cycloalkyl group, heterocyclic group, aralkyl group, a (C_3-C_6)cycloalkyl-alkyl group, and heterocyclyl-alkyl group;

optionally, R^4 and R^5 together with the nitrogen to which they are attached represent morpholino, pyrrolidino, piperidino, imidazol-1-yl, piperazino, thiamorpholino, azepino or perhydro-1,4-diazepin-1-yl groups each optionally substituted by one or more moieties selected from the group consisting of lower alkyl, hydroxy, lower alkoxy lower alkyl, an aromatic group, a (C_3-C_6)cycloalkyl group, a heterocyclic group, an aralkyl group, a (C_3-C_6)cycloalkyl-alkyl group, and a heterocyclyl-alkyl group; and

n is an integer from 0 to 3;

provided that when R is an unsubstituted indol-3-yl then R^1 is not $-NH_2$;

to said recipient.

39-40 (Cancelled)

41. (Original) A compound according to Claim 18 wherein R is substituted with one or more substituents, each independently selected from the group consisting of halogens, lower alkyl groups, R^3O-, hydroxyl, HOC(O), $R^3OC(O)-$, $R^3OC(O)R^6-$, R^3OR^6-, trihalomethyl, trihalomethylcarbonyl, nitro, $-C(O)NR^4R^5$, $-NR^4R^5$, R^3CO-, $(CH_2)_n-R^7$, $-C(O)(CH_2)_nR^7$, -

$O(CH_2)_nR^7$, $-C(O)NR^4(CH_2)_nR^7$, $-C(O)O(CH_2)_nR^7$, $-OC(O)(CH_2)_nR^7$, $-NR^4C(O)(CH_2)_nR^7$, $-R^6NR^4R^5$, $-R^6N(R^4)-R^6-R^7$, $-R^6N(R^6-R^7)_2$, $-R^6C(O)NR^4(CH_2)_nR^7$, $-R^6C(O)O(CH_2)_nR^7$, $-R^6OC(O)(CH_2)_nR^7$, $-R^6NR^4C(O)(CH_2)_nR^7$, $-R^6CH(C(O)OR^4)(^{NR5C}(O)R^4)$, an optionally substituted aryl and an optionally substituted aralkyl group;

wherein the optionally substituted aryl and optionally substituted aralkyl groups are optionally substituted with one or more substituents selected from the group consisting of halogen, trihalomethyl, hydroxyl, $-NR^4R^5$, nitro, $-CONR^4R^5$, lower alkyl group, R^3O-, -C(O)OR4 and $-OC(O)R^3$;

R^6 is a lower alkyl group or an aryl group; and

R^7 is alkoxy, haloalkyl, loweralkyl piperazine, hydroxyl, R^3O-, $R^3C(O)-$ or $-NR^4R^5$.

42. (Cancelled)

43. (Currently Amended) A compound of claim ~~42~~41, wherein R is pyrrol-2-yl~~,~~ or pyrrol-3-yl~~, indol 2 yl, indol 3 yl, azaindol 3 yl, pyrazol 4 yl, imidazol 2 yl, imidazol 4 yl, thien 2 yl or quinolin 5 yl~~.

44. (Cancelled)

45. (Currently Amended) A compound of Claim [44] 43, wherein R is optionally substituted with one or more moieties selected from the group consisting of Br, Cl, F, aminomethyl, N,N-dimethylaminomethyl, carboxy, carboxymethyl, carboxyethyl, carbonylmethyl, carbonylethyl, methoxycarbonyl, ethoxycarbonyl, phenyl, 4-morpholinomethyl, $-C(O)-O-(CH_2)_2-N(Me)_2$, $-C(O)-O-(CH_2)_2-N(Et)_2$, $-C(O)-O-CH_2-N(Me)_2$, $-C(O)-O-(CH_2)_2-N(Me)_2$, $-C(O)-NH-(CH_2)_2-N(Me)_2$, $-CH_2-NH-C(O)-CF_3$, $(CH_2)_n-R^7$ and an optionally substituted moiety selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl and phenyl, where said optionally substituted moiety is optionally substituted with one or more of Br, Cl, F, hydroxyl, nitro, amino or lower alkyl.

46. (New) A compound of claim 18 wherein R^1 is pyrazinyl or phenyl and R is pyrrolyl substituted by one or more methyl and diethylaminoethyl.

47. (New) A compound of claim 46 wherein the compound is 4-[4-(2-diethylamino-ethyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-5-pyrazin-2-yl-2,4-dihydropyrazol-3-one.